Pembrolizumab + Mogamulizumab

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cutaneous T Cell Lymphoma

Conditions

Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome

Trial Timeline

Dec 6, 2023 → Apr 1, 2027

NCT ID

NCT05956041

About Pembrolizumab + Mogamulizumab

Pembrolizumab + Mogamulizumab is a phase 2 stage product being developed by Merck for Cutaneous T Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05956041. Target conditions include Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome.

What happened to similar drugs?

7 of 20 similar drugs in Cutaneous T Cell Lymphoma were approved

Approved (7) Terminated (1) Active (12)

✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved

✅ONTAKEisaiApproved

✅MogamulizumabKyowa KirinApproved

✅Clopidogrel + TicagrelorAstraZenecaApproved

✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved

✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05956041	Phase 2	Recruiting	Dec 6, 2023	Apr 1, 2027	Cutaneous T Cell Lymphoma

Competing Products

20 competing products in Cutaneous T Cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
ONTAK (denileukin difitox, DAB389IL-2)	Eisai	Approved	43
ONTAK	Eisai	Approved	43
E7777 9 mcg/kg	Eisai	Phase 3	40
ONTAK	Eisai	Approved	43
Mogamulizumab	Kyowa Kirin	Approved	47
Mogamulizumab + Brentuximab vedotin	Kyowa Kirin	Phase 1	36
Mogamulizumab	Kyowa Kirin	Phase 2	39
KW-0761 + Vorinostat	Kyowa Kirin	Phase 3	40
Enzastaurin	Eli Lilly	Phase 2	35
Clopidogrel + Ticagrelor	AstraZeneca	Approved	43
Pembrolizumab	Merck	Phase 2	42
Comparator: vorinostat	Merck	Pre-clinical	26
Pembrolizumab	Merck	Phase 2	39
TR701 FA	Merck	Phase 2	35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months	Merck	Phase 2	35
Pembrolizumab	Merck	Phase 2	42
Tulisokibart + Placebo	Merck	Phase 2	39
Aspirin + Ipilimumab + Pembrolizumab	Merck	Phase 2	35
TR-701 FA + Linezolid	Merck	Phase 3	40
Pimasertib + Dacarbazine	Merck	Phase 2	35